secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2026-05-11T23:59:59+00:00
Accession:  0001193125-26-215662
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health gets Dutch authorization for first-in-human trial of RJVA-001 gene therapy for T2D
--------------------------------------------------------------------------------

- Received Clinical Trial Application authorization in the Netherlands for Phase 1/2 first-in-human study of RJVA-001.
- RJVA-001 is the first AAV gene therapy candidate to enter clinical development for type 2 diabetes.
- First patient dosing and preliminary data expected in the second half of 2026, subject to site activation.
- Rejuva clinical development funded within existing cash runway into early 2027; no change to capital plans.
- Fractyl becomes dual clinical-stage with Revita in pivotal development and Rejuva entering first-in-human studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526215662/0001193125-26-215662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526215662/guts-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-215662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer